Loading…

553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition

BackgroundClinical data demonstrates increased antigen presentation diversity is an important factor in determining response rates to checkpoint inhibitors.1 In addition to tumor mutational burden, increased HLA heterozygosity and HLA evolutionary diversity are non-overlapping factors which further...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2021-11, Vol.9 (Suppl 2), p.A583-A583
Main Authors: Joyce, Peter, Quibell, Martin, Shiers, Jason, Tong, Carmen, Clark, Kristopher, Ternette, Nicola, Anderton, Kate, Sette, Jessica, Paes, Wayne, Leishman, Andrew
Format: Article
Language:English
Subjects:
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A583
container_issue Suppl 2
container_start_page A583
container_title Journal for immunotherapy of cancer
container_volume 9
creator Joyce, Peter
Quibell, Martin
Shiers, Jason
Tong, Carmen
Clark, Kristopher
Ternette, Nicola
Anderton, Kate
Sette, Jessica
Paes, Wayne
Leishman, Andrew
description BackgroundClinical data demonstrates increased antigen presentation diversity is an important factor in determining response rates to checkpoint inhibitors.1 In addition to tumor mutational burden, increased HLA heterozygosity and HLA evolutionary diversity are non-overlapping factors which further diversify the immunopeptidome and improve clinical response to checkpoint therapies.2 3 Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an enzyme that trims peptides loaded into classical and nonclassical MHC Class I molecules.4 5 Ablation of mouse ERAAP modifies the immunopeptidome, resulting in improved immunogenicity, generation of CD8+ T cell responses and tumor growth inhibition.6 7 We report the characterisation of ERAP1 inhibitors in syngeneic tumor models and development of biomarkers to enable translation of this mechanism into the clinic.MethodsHuman and mouse cancer cell lines treated with ERAP1 inhibitors were assessed by immunopeptidomics8 to profile peptide repertoire changes. ERAP1 inhibitor with and without checkpoint inhibition were used to treat syngeneic mouse tumor models, followed by analysing effects on the T cell receptor (TCR) repertoire, RNA sequencing profile, immune cell infiltration and tumor growth inhibition.ResultsExtensive analysis of the immunopeptidomes of diverse cancer cell lines robustly show that ERAP1 inhibition modulates the cancer-related antigen repertoire across diverse ERAP1 and HLA genotypes and cancer-type backgrounds. ERAP1 inhibition drives changes in T cell activation and response, leading to increased T cell infiltration into CT26 syngeneic tumors and alteration of the TCR repertoire at early and late timepoints in tumor growth. Consistent peptide length changes in the immunopeptidome, caused by ERAP1 inhibition, is a proof of mechanism biomarker, whilst tumor immunohistochemisty, TCR repertoire analysis and RNA sequencing are potential proof of principle biomarkers that can all be translated into the clinic. Importantly, the antigen and T cell changes we see following ERAP1 inhibition lead to robust tumor growth inhibition in different syngeneic mouse models when combined with anti-PD-1. We are also exploring the potential of ERAP1 inhibitors to enhance tumour immune responses in combination with additional therapies (e.g. chemotherapy and radiotherapy), across different tumor microenvironments.ConclusionsGrey Wolf Therapeutics ERAP1 inhibitors significantly modify the immunopeptidome and combination with anti
doi_str_mv 10.1136/jitc-2021-SITC2021.553
format article
fullrecord <record><control><sourceid>proquest_9YT</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_f77fbe78c6a14420843d4d1a5af88195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_f77fbe78c6a14420843d4d1a5af88195</doaj_id><sourcerecordid>2595870620</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1853-13e0a0a31608ff0d5a6bacf86b5ea37664069cf082fcc834c1a647decf4a95d3</originalsourceid><addsrcrecordid>eNpFkcFq3DAQhk2hkJDmFYKg1zqVLEvWHsOStAuBlnbvYiyNdmVsyZW0Lb310ofo6-VJYncbepqf4eOfga-qbhi9ZYzL94Mvpm5ow-qvu_12DbdC8FfVZUMFq1nbyIvqOueBUsoo50qpy-rPQjz9-v3gUy61D7UZIWfiw9H3vsSUSXTk_svdZ0ZgLJhIOSLx03QKcca5eBsnXBEDwWB6R2zy3304ECDWO4cJQ_FQ0JI9MTiOJGGeY8hIRgS7giWScppiIocUf5Tjy2Ufw5vqtYMx4_W_eVXtH-7324_146cPu-3dY90zJXjNOFKgwJmkyjlqBcgejFOyFwi8k7KlcmMcVY0zRvHWMJBtZ9G4FjbC8qtqd661EQY9Jz9B-qkjeP13EdNBQyrejKhd17keO2UksLZtqGq5bS0DAU4pthFL19tz15zitxPmood4SmH5XjdiI1RHZUMXqjlT_TT8BxjVq0S9StSrO_0iUS-K-DNhbZV0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2595870620</pqid></control><display><type>article</type><title>553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition</title><source>BMJ Open Access Journals</source><creator>Joyce, Peter ; Quibell, Martin ; Shiers, Jason ; Tong, Carmen ; Clark, Kristopher ; Ternette, Nicola ; Anderton, Kate ; Sette, Jessica ; Paes, Wayne ; Leishman, Andrew</creator><creatorcontrib>Joyce, Peter ; Quibell, Martin ; Shiers, Jason ; Tong, Carmen ; Clark, Kristopher ; Ternette, Nicola ; Anderton, Kate ; Sette, Jessica ; Paes, Wayne ; Leishman, Andrew</creatorcontrib><description>BackgroundClinical data demonstrates increased antigen presentation diversity is an important factor in determining response rates to checkpoint inhibitors.1 In addition to tumor mutational burden, increased HLA heterozygosity and HLA evolutionary diversity are non-overlapping factors which further diversify the immunopeptidome and improve clinical response to checkpoint therapies.2 3 Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an enzyme that trims peptides loaded into classical and nonclassical MHC Class I molecules.4 5 Ablation of mouse ERAAP modifies the immunopeptidome, resulting in improved immunogenicity, generation of CD8+ T cell responses and tumor growth inhibition.6 7 We report the characterisation of ERAP1 inhibitors in syngeneic tumor models and development of biomarkers to enable translation of this mechanism into the clinic.MethodsHuman and mouse cancer cell lines treated with ERAP1 inhibitors were assessed by immunopeptidomics8 to profile peptide repertoire changes. ERAP1 inhibitor with and without checkpoint inhibition were used to treat syngeneic mouse tumor models, followed by analysing effects on the T cell receptor (TCR) repertoire, RNA sequencing profile, immune cell infiltration and tumor growth inhibition.ResultsExtensive analysis of the immunopeptidomes of diverse cancer cell lines robustly show that ERAP1 inhibition modulates the cancer-related antigen repertoire across diverse ERAP1 and HLA genotypes and cancer-type backgrounds. ERAP1 inhibition drives changes in T cell activation and response, leading to increased T cell infiltration into CT26 syngeneic tumors and alteration of the TCR repertoire at early and late timepoints in tumor growth. Consistent peptide length changes in the immunopeptidome, caused by ERAP1 inhibition, is a proof of mechanism biomarker, whilst tumor immunohistochemisty, TCR repertoire analysis and RNA sequencing are potential proof of principle biomarkers that can all be translated into the clinic. Importantly, the antigen and T cell changes we see following ERAP1 inhibition lead to robust tumor growth inhibition in different syngeneic mouse models when combined with anti-PD-1. We are also exploring the potential of ERAP1 inhibitors to enhance tumour immune responses in combination with additional therapies (e.g. chemotherapy and radiotherapy), across different tumor microenvironments.ConclusionsGrey Wolf Therapeutics ERAP1 inhibitors significantly modify the immunopeptidome and combination with anti PD-1 leads to significant TCR repertoire change, T cell infiltration and tumor growth inhibition in syngeneic mouse tumor models. These data provide the foundation from which we will explore the potential of our first-in-class ERAP1 inhibitor development candidate in the clinic, as well as identifying useful biomarkers to demonstrate desired biological activity.ReferencesRizvi N, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 2015;348(6230):124–128.Chowell D, uc G T Morris LGT,2 3, Grigg CM, et al Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 2018;359 (6375):582–587.Chowell D, Chirag Krishna, Federica Pierini, et al Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nature Medicine 2019;25(11):1715–1720.Shastri N, Nagarajan N, Lind KC, et al. Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum. Curr Opin Immunol 2014;26:123–127.Mpakali A, Maben Z, Stern LJ, et al. Molecular pathways for antigenic peptide generation by ER aminopeptidase 1. Mol Immunol 2018;13:50–57.James E, Bailey I, Sugiyarto G, et al. Induction of protective antitumor immunity through attenuation of ERAAP function. J Immunol 2013;190(11):5839–5846.Manguso RT, Pope, HW, MD Zimmer, et al In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 2017;547(7664):413–418.Purcell AW, Ramarathinam SH, Ternette N. Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics. Nat Protoc 2019;14(6):1687–1707.</description><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1136/jitc-2021-SITC2021.553</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd</publisher><subject>Antigens ; Biomarkers ; Cancer ; Endoplasmic reticulum ; Immunotherapy ; Lymphocytes ; Peptides ; Regular and Young Investigator Award Abstracts ; T cell receptors</subject><ispartof>Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A583-A583</ispartof><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2595870620/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2595870620?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,55350,75126,77660,77686</link.rule.ids><linktorsrc>$$Uhttps://jitc.bmj.com/content/9/Suppl_2/A583.full$$EView_record_in_BMJ_Publishing_Group_Ltd$$FView_record_in_$$GBMJ_Publishing_Group_Ltd</linktorsrc></links><search><creatorcontrib>Joyce, Peter</creatorcontrib><creatorcontrib>Quibell, Martin</creatorcontrib><creatorcontrib>Shiers, Jason</creatorcontrib><creatorcontrib>Tong, Carmen</creatorcontrib><creatorcontrib>Clark, Kristopher</creatorcontrib><creatorcontrib>Ternette, Nicola</creatorcontrib><creatorcontrib>Anderton, Kate</creatorcontrib><creatorcontrib>Sette, Jessica</creatorcontrib><creatorcontrib>Paes, Wayne</creatorcontrib><creatorcontrib>Leishman, Andrew</creatorcontrib><title>553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition</title><title>Journal for immunotherapy of cancer</title><addtitle>J Immunother Cancer</addtitle><description>BackgroundClinical data demonstrates increased antigen presentation diversity is an important factor in determining response rates to checkpoint inhibitors.1 In addition to tumor mutational burden, increased HLA heterozygosity and HLA evolutionary diversity are non-overlapping factors which further diversify the immunopeptidome and improve clinical response to checkpoint therapies.2 3 Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an enzyme that trims peptides loaded into classical and nonclassical MHC Class I molecules.4 5 Ablation of mouse ERAAP modifies the immunopeptidome, resulting in improved immunogenicity, generation of CD8+ T cell responses and tumor growth inhibition.6 7 We report the characterisation of ERAP1 inhibitors in syngeneic tumor models and development of biomarkers to enable translation of this mechanism into the clinic.MethodsHuman and mouse cancer cell lines treated with ERAP1 inhibitors were assessed by immunopeptidomics8 to profile peptide repertoire changes. ERAP1 inhibitor with and without checkpoint inhibition were used to treat syngeneic mouse tumor models, followed by analysing effects on the T cell receptor (TCR) repertoire, RNA sequencing profile, immune cell infiltration and tumor growth inhibition.ResultsExtensive analysis of the immunopeptidomes of diverse cancer cell lines robustly show that ERAP1 inhibition modulates the cancer-related antigen repertoire across diverse ERAP1 and HLA genotypes and cancer-type backgrounds. ERAP1 inhibition drives changes in T cell activation and response, leading to increased T cell infiltration into CT26 syngeneic tumors and alteration of the TCR repertoire at early and late timepoints in tumor growth. Consistent peptide length changes in the immunopeptidome, caused by ERAP1 inhibition, is a proof of mechanism biomarker, whilst tumor immunohistochemisty, TCR repertoire analysis and RNA sequencing are potential proof of principle biomarkers that can all be translated into the clinic. Importantly, the antigen and T cell changes we see following ERAP1 inhibition lead to robust tumor growth inhibition in different syngeneic mouse models when combined with anti-PD-1. We are also exploring the potential of ERAP1 inhibitors to enhance tumour immune responses in combination with additional therapies (e.g. chemotherapy and radiotherapy), across different tumor microenvironments.ConclusionsGrey Wolf Therapeutics ERAP1 inhibitors significantly modify the immunopeptidome and combination with anti PD-1 leads to significant TCR repertoire change, T cell infiltration and tumor growth inhibition in syngeneic mouse tumor models. These data provide the foundation from which we will explore the potential of our first-in-class ERAP1 inhibitor development candidate in the clinic, as well as identifying useful biomarkers to demonstrate desired biological activity.ReferencesRizvi N, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 2015;348(6230):124–128.Chowell D, uc G T Morris LGT,2 3, Grigg CM, et al Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 2018;359 (6375):582–587.Chowell D, Chirag Krishna, Federica Pierini, et al Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nature Medicine 2019;25(11):1715–1720.Shastri N, Nagarajan N, Lind KC, et al. Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum. Curr Opin Immunol 2014;26:123–127.Mpakali A, Maben Z, Stern LJ, et al. Molecular pathways for antigenic peptide generation by ER aminopeptidase 1. Mol Immunol 2018;13:50–57.James E, Bailey I, Sugiyarto G, et al. Induction of protective antitumor immunity through attenuation of ERAAP function. J Immunol 2013;190(11):5839–5846.Manguso RT, Pope, HW, MD Zimmer, et al In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 2017;547(7664):413–418.Purcell AW, Ramarathinam SH, Ternette N. Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics. Nat Protoc 2019;14(6):1687–1707.</description><subject>Antigens</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Endoplasmic reticulum</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Peptides</subject><subject>Regular and Young Investigator Award Abstracts</subject><subject>T cell receptors</subject><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpFkcFq3DAQhk2hkJDmFYKg1zqVLEvWHsOStAuBlnbvYiyNdmVsyZW0Lb310ofo6-VJYncbepqf4eOfga-qbhi9ZYzL94Mvpm5ow-qvu_12DbdC8FfVZUMFq1nbyIvqOueBUsoo50qpy-rPQjz9-v3gUy61D7UZIWfiw9H3vsSUSXTk_svdZ0ZgLJhIOSLx03QKcca5eBsnXBEDwWB6R2zy3304ECDWO4cJQ_FQ0JI9MTiOJGGeY8hIRgS7giWScppiIocUf5Tjy2Ufw5vqtYMx4_W_eVXtH-7324_146cPu-3dY90zJXjNOFKgwJmkyjlqBcgejFOyFwi8k7KlcmMcVY0zRvHWMJBtZ9G4FjbC8qtqd661EQY9Jz9B-qkjeP13EdNBQyrejKhd17keO2UksLZtqGq5bS0DAU4pthFL19tz15zitxPmood4SmH5XjdiI1RHZUMXqjlT_TT8BxjVq0S9StSrO_0iUS-K-DNhbZV0</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Joyce, Peter</creator><creator>Quibell, Martin</creator><creator>Shiers, Jason</creator><creator>Tong, Carmen</creator><creator>Clark, Kristopher</creator><creator>Ternette, Nicola</creator><creator>Anderton, Kate</creator><creator>Sette, Jessica</creator><creator>Paes, Wayne</creator><creator>Leishman, Andrew</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope></search><sort><creationdate>20211101</creationdate><title>553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition</title><author>Joyce, Peter ; Quibell, Martin ; Shiers, Jason ; Tong, Carmen ; Clark, Kristopher ; Ternette, Nicola ; Anderton, Kate ; Sette, Jessica ; Paes, Wayne ; Leishman, Andrew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1853-13e0a0a31608ff0d5a6bacf86b5ea37664069cf082fcc834c1a647decf4a95d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Endoplasmic reticulum</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Peptides</topic><topic>Regular and Young Investigator Award Abstracts</topic><topic>T cell receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joyce, Peter</creatorcontrib><creatorcontrib>Quibell, Martin</creatorcontrib><creatorcontrib>Shiers, Jason</creatorcontrib><creatorcontrib>Tong, Carmen</creatorcontrib><creatorcontrib>Clark, Kristopher</creatorcontrib><creatorcontrib>Ternette, Nicola</creatorcontrib><creatorcontrib>Anderton, Kate</creatorcontrib><creatorcontrib>Sette, Jessica</creatorcontrib><creatorcontrib>Paes, Wayne</creatorcontrib><creatorcontrib>Leishman, Andrew</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Joyce, Peter</au><au>Quibell, Martin</au><au>Shiers, Jason</au><au>Tong, Carmen</au><au>Clark, Kristopher</au><au>Ternette, Nicola</au><au>Anderton, Kate</au><au>Sette, Jessica</au><au>Paes, Wayne</au><au>Leishman, Andrew</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><stitle>J Immunother Cancer</stitle><date>2021-11-01</date><risdate>2021</risdate><volume>9</volume><issue>Suppl 2</issue><spage>A583</spage><epage>A583</epage><pages>A583-A583</pages><eissn>2051-1426</eissn><abstract>BackgroundClinical data demonstrates increased antigen presentation diversity is an important factor in determining response rates to checkpoint inhibitors.1 In addition to tumor mutational burden, increased HLA heterozygosity and HLA evolutionary diversity are non-overlapping factors which further diversify the immunopeptidome and improve clinical response to checkpoint therapies.2 3 Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an enzyme that trims peptides loaded into classical and nonclassical MHC Class I molecules.4 5 Ablation of mouse ERAAP modifies the immunopeptidome, resulting in improved immunogenicity, generation of CD8+ T cell responses and tumor growth inhibition.6 7 We report the characterisation of ERAP1 inhibitors in syngeneic tumor models and development of biomarkers to enable translation of this mechanism into the clinic.MethodsHuman and mouse cancer cell lines treated with ERAP1 inhibitors were assessed by immunopeptidomics8 to profile peptide repertoire changes. ERAP1 inhibitor with and without checkpoint inhibition were used to treat syngeneic mouse tumor models, followed by analysing effects on the T cell receptor (TCR) repertoire, RNA sequencing profile, immune cell infiltration and tumor growth inhibition.ResultsExtensive analysis of the immunopeptidomes of diverse cancer cell lines robustly show that ERAP1 inhibition modulates the cancer-related antigen repertoire across diverse ERAP1 and HLA genotypes and cancer-type backgrounds. ERAP1 inhibition drives changes in T cell activation and response, leading to increased T cell infiltration into CT26 syngeneic tumors and alteration of the TCR repertoire at early and late timepoints in tumor growth. Consistent peptide length changes in the immunopeptidome, caused by ERAP1 inhibition, is a proof of mechanism biomarker, whilst tumor immunohistochemisty, TCR repertoire analysis and RNA sequencing are potential proof of principle biomarkers that can all be translated into the clinic. Importantly, the antigen and T cell changes we see following ERAP1 inhibition lead to robust tumor growth inhibition in different syngeneic mouse models when combined with anti-PD-1. We are also exploring the potential of ERAP1 inhibitors to enhance tumour immune responses in combination with additional therapies (e.g. chemotherapy and radiotherapy), across different tumor microenvironments.ConclusionsGrey Wolf Therapeutics ERAP1 inhibitors significantly modify the immunopeptidome and combination with anti PD-1 leads to significant TCR repertoire change, T cell infiltration and tumor growth inhibition in syngeneic mouse tumor models. These data provide the foundation from which we will explore the potential of our first-in-class ERAP1 inhibitor development candidate in the clinic, as well as identifying useful biomarkers to demonstrate desired biological activity.ReferencesRizvi N, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 2015;348(6230):124–128.Chowell D, uc G T Morris LGT,2 3, Grigg CM, et al Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 2018;359 (6375):582–587.Chowell D, Chirag Krishna, Federica Pierini, et al Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nature Medicine 2019;25(11):1715–1720.Shastri N, Nagarajan N, Lind KC, et al. Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum. Curr Opin Immunol 2014;26:123–127.Mpakali A, Maben Z, Stern LJ, et al. Molecular pathways for antigenic peptide generation by ER aminopeptidase 1. Mol Immunol 2018;13:50–57.James E, Bailey I, Sugiyarto G, et al. Induction of protective antitumor immunity through attenuation of ERAAP function. J Immunol 2013;190(11):5839–5846.Manguso RT, Pope, HW, MD Zimmer, et al In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 2017;547(7664):413–418.Purcell AW, Ramarathinam SH, Ternette N. Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics. Nat Protoc 2019;14(6):1687–1707.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd</pub><doi>10.1136/jitc-2021-SITC2021.553</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier EISSN: 2051-1426
ispartof Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A583-A583
issn 2051-1426
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_f77fbe78c6a14420843d4d1a5af88195
source BMJ Open Access Journals
subjects Antigens
Biomarkers
Cancer
Endoplasmic reticulum
Immunotherapy
Lymphocytes
Peptides
Regular and Young Investigator Award Abstracts
T cell receptors
title 553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A18%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_9YT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=553%E2%80%85First-in-class%20inhibitors%20of%20ERAP1%20alter%20the%20immunopeptidome%20of%20cancer,%20driving%20a%20differentiated%20T%20cell%20response%20leading%20to%20tumor%20growth%20inhibition&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Joyce,%20Peter&rft.date=2021-11-01&rft.volume=9&rft.issue=Suppl%202&rft.spage=A583&rft.epage=A583&rft.pages=A583-A583&rft.eissn=2051-1426&rft_id=info:doi/10.1136/jitc-2021-SITC2021.553&rft_dat=%3Cproquest_9YT%3E2595870620%3C/proquest_9YT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1853-13e0a0a31608ff0d5a6bacf86b5ea37664069cf082fcc834c1a647decf4a95d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2595870620&rft_id=info:pmid/&rfr_iscdi=true